Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis: A Treat-to-Target Analysis of Adults with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib
Acta Dermato-Venereologica · 2024
DOI: 10.2340/actadv.v104.18452 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Dermato-Venereologica, 2024. Verfasst von Shawn G Kwatra und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. kwatra.shawn@gmail.com. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Heterocyclic Compounds, 3-Ring, Severity of Illness Index. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
A treat-to-target approach was recently developed to guide systemic treatment for adults with atopic dermatitis (AD). Recommendations outlined criteria for a 3-month initial acceptable treatment target and a 6-month optimal target, evaluated using global assessment of patient-reported disease severity, as well as Eczema Area and Severity Index, itch assessed on an 11-point numerical rating scale, Dermatology Life Quality Index, or Patient-Oriented Eczema Measure. Achievement of these targets with once-daily upadacitinib (15 mg and 30 mg) monotherapy was evaluated using integrated adult data from the Measure Up 1 and 2 phase 3 studies. Among the 852 patients treated with upadacitinib 15 mg or 30 mg, the 3-month initial acceptable target was achieved by >80%, >78%, and ≥87% of patients, and the 6-month optimal target was achieved by ≥53%, >61%, and >73% of patients at weeks 2, 16, and 52, respectively. Achievement of all 6 individual criteria for each of the target goals also increased over time. These findings suggest that upadacitinib 15 mg and 30 mg may help improve standards of care in patients with moderate-to-severe AD by achieving 6-month target goals at 16 weeks and as early as 2 weeks for most patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. kwatra.shawn@gmail.com.
- University Medical Center Utrecht, Utrecht, the Netherlands.
- Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
- Department of Dermatology & Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
- Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
- AbbVie Inc., North Chicago, IL, USA.
Zitieren
APA
Kwatra, S. G., De Bruin-Weller, M., Silverberg, J. I., Lio, P., Deleuran, M., Aydin, H., Calimlim, B. M., Lane, M. C., Liu, Y., Ofori, S., & Weidinger, S. (2024). Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis: A Treat-to-Target Analysis of Adults with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib. Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v104.18452
Vancouver
Kwatra SG, De Bruin-Weller M, Silverberg JI, Lio P, Deleuran M, Aydin H, et al. Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis: A Treat-to-Target Analysis of Adults with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib. Acta Dermato-Venereologica. 2024. doi:10.2340/actadv.v104.18452
BibTeX
@article{Kwatra2024,
author = {Kwatra, Shawn G and De Bruin-Weller, Marjolein and Silverberg, Jonathan I and Lio, Peter and Deleuran, Mette and Aydin, Handan and Calimlim, Brian M and Lane, Michael C and Liu, Yingyi and Ofori, Sarah and Weidinger, Stephan},
title = {Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis: A Treat-to-Target Analysis of Adults with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib},
journal = {Acta Dermato-Venereologica},
year = {2024},
doi = {10.2340/actadv.v104.18452}
}
EUVIMED